Orthocell Ltd (ASX: OCC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Orthocell Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $76.40 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 209.33 million
Earnings per share -0.037
Dividend per share N/A
Year To Date Return -7.32%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Orthocell Ltd (ASX: OCC)
    Latest News

    A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
    Healthcare Shares

    Orthocell (ASX:OCC) share price surges 13% on study success

    Shares in the medical company are surging today.

    Read more »

    ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
    Healthcare Shares

    Why the Orthocell (ASX:OCC) share price is flying higher today

    Orthocell reports promising results on nerve repair for patients following serious injury.

    Read more »

    medical doctor performing surgery using surgical instruments
    Healthcare Shares

    Here's why the Orthocell (ASX:OCC) share price is on the move today

    The company has taken another step in getting one of its star products internationally patented.

    Read more »

    Five stacked building blocks with green arrows, indicating rising inflation or share prices
    Healthcare Shares

    The Orthocell (ASX:OCC) share price is on the rise today. Here's why

    The Orthocell Limited (ASX: OCC) share price is up with news the company's hoping to fast-track its US approval after…

    Read more »

    Tooth and dentist tool on blue background
    Share Market News

    Why the Orthocell (ASX:OCC) share price is edging higher today

    The Orthocell Ltd (ASX: OCC) share price is edging higher today following a positive update in regards to CelGro. Here's…

    Read more »

    A male ASX investor wearing glasses and a beanie and denim shirt puts his hand to his chin wondering whether to buy ASX shares
    Share Market News

    Why is the Orthocell (ASX:OCC) share price falling today?

    The Orthocell Ltd (ASX: OCC) share price is sinking this afternoon despite a positive update on its CelGro product.

    Read more »

    Surge in ASX share price represented by happy woman pointing to her big smile
    Share Market News

    Why the Orthocell (ASX:OCC) share price is on the rise

    The Orthocell Ltd (ASX: OCC) share price is rising after the company announced an earlier than expected positive update. Here's…

    Read more »

    ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
    Share Market News

    Why the Orthocell (ASX:OCC) share price is rocketing 23% higher

    The Orthocell Ltd (ASX: OCC) share price is one of the best performers on the market today. This comes after…

    Read more »

    A medical researcher works on a bichip, indicating share price movement in ASX tech companies
    Share Market News

    Why the Orthocell (ASX:OCC) share price has popped 6% today

    The Orthocell Ltd (ASX: OCC) share price is surging higher today. This comes after the company received Australian market approval…

    Read more »

    asx medical share price represented by x-ray or people shaking hands
    Share Market News

    Why the Orthocell (ASX:OCC) share price is edging higher today

    The Orthocell (ASX: OCC) share price is edging higher as the company said it has completed an important step in…

    Read more »

    Share Market News

    Orthocell (ASX:OCC) share price jumps 17% on positive clinical trials

    The Orthocell Ltd (ASX: OCC) share price has rocketed more than 17% after positive results for the company's nerve repair…

    Read more »

    a woman
    Share Market News

    The Orthocell share price is going nuts on claims of a blockbuster medical breakthrough

    Orthocell Ltd (ASX: OCC) is reporting a blockbuster medical breakthrough.

    Read more »

    OCC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Orthocell Ltd

    Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialisation of cell therapies and related technologies. Its product includes CelGro is a naturally derived collagen medical device for tissue repair and Ortho-ATI is a first-in-class cell therapy for the treatment of chronic tendon injuries.

    OCC Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    24 May 2024 $0.38 $0.01 2.70% 43,900 $0.38 $0.38 $0.38
    23 May 2024 $0.37 $0.00 0.00% 50,000 $0.37 $0.37 $0.37
    22 May 2024 $0.37 $-0.01 -2.67% 575,180 $0.38 $0.38 $0.37
    21 May 2024 $0.38 $0.00 0.00% 31,181 $0.38 $0.38 $0.38
    20 May 2024 $0.38 $-0.02 -5.13% 326,561 $0.38 $0.39 $0.38
    17 May 2024 $0.39 $0.01 2.60% 160,062 $0.39 $0.40 $0.38
    16 May 2024 $0.39 $0.01 2.63% 26,835 $0.38 $0.39 $0.38
    15 May 2024 $0.38 $-0.02 -5.00% 17,711 $0.40 $0.40 $0.38
    14 May 2024 $0.40 $0.01 2.56% 255,799 $0.40 $0.41 $0.39
    13 May 2024 $0.39 $0.02 5.33% 118,501 $0.38 $0.39 $0.38
    10 May 2024 $0.38 $0.01 2.70% 86,681 $0.37 $0.38 $0.37
    09 May 2024 $0.37 $0.00 0.00% 97,623 $0.37 $0.37 $0.37
    08 May 2024 $0.37 $-0.01 -2.67% 190,856 $0.38 $0.38 $0.37
    07 May 2024 $0.38 $-0.02 -5.13% 144,537 $0.39 $0.39 $0.38
    06 May 2024 $0.39 $-0.01 -2.53% 75,275 $0.40 $0.40 $0.39
    03 May 2024 $0.40 $0.01 2.60% 74,119 $0.39 $0.40 $0.39
    02 May 2024 $0.39 $0.01 2.63% 210,000 $0.39 $0.39 $0.39
    01 May 2024 $0.38 $-0.01 -2.60% 258,649 $0.39 $0.39 $0.38
    30 Apr 2024 $0.39 $0.01 2.63% 303,964 $0.40 $0.40 $0.39
    29 Apr 2024 $0.38 $0.01 2.67% 35,471 $0.39 $0.39 $0.38

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    24 Apr 2024 John Wielen Buy 20,000 $7,622
    On-market trade.
    15 Apr 2024 John Wielen Buy 35,000 $13,646
    On-market trade.
    17 Jan 2024 Kim Beazley AC Issued 2,000,000 $820,000
    Issue of options.
    20 Nov 2023 Fiona Wood Issued 2,000,000 $820,000
    Issue of options.
    15 Nov 2023 John Wielen Issued 250,000 $91,250
    Issue of securities.
    07 Nov 2023 Paul Anderson Issued 500,000 $192,500
    Issue of options.
    30 Oct 2023 John Wielen Buy 20,000 $7,239
    On-market trade.
    13 Jun 2023 Paul Anderson Buy 9,907 $3,516
    On-market trade.
    09 Jun 2023 Paul Anderson Buy 31,343 $11,254
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Professor Fiona Melanie Wood Non-Executive Director Nov 2023
    --
    Mr Paul Frederick Anderson Managing Director Mar 2006
    Mr Anderson has over 20 years' experience in the medical device and regenerative medicine fields with experience in bridging the gap between research and clinical practice in the development of emerging medical technologies. He also has experience in the establishment of GMP manufacturing facilities and scale-up activities for cell therapies and biological medical devices, and the associated regulatory filings.
    Dr Ravi Thadhani Non-Executive Director Mar 2023
    Dr Thadhani has experience in patient care, advancing novel research programs, US regulatory pathways and commercialisation of devices and therapeutics. He served on multiple US FDA advisory committees in the musculoskeletal, cardiovascular and renal sectors providing expert guidance to the FDA and companies regarding the regulatory requirements for approval of medical devices and therapeutics, High-profile healthcare administration roles, most recently professor of medicine at Harvard Medical School and chief academic officer and dean for faculty affairs for Mass General Brigham hospital, research enterprise Expert advisor to multiple global pharmaceutical companies including Sandoz, Shire, Novartis, Celgene, Bayer and Reata on clinical trial design, execution and data monitoring Co-author of more than 300 scientific publications.
    Mr John Van Der Wielen Non-Executive ChairmanNon-Executive Director Jun 2023
    Mr Wielen has 35 years international experience in wealth management, private banking, investments, and insurance, in the UK, Luxembourg, Malaysia and Australia. He has held senior executive positions with several national and global financialservices groups. Most recently Mr Van Der Wielen wasthe CEO and MD of HBF Health Ltd for over five years. Mr Van Der Wielens other previous executive positions include CEO (UK & International) of Friends Life UK, Managing Director (Wealth) of ANZ, CEO of Clerical Medical, Halifax Life & Heidelberger Leben and CEO of Lloyds Banking Group/HBOS Plc.
    Hon Kim Beazley AC Non-Executive Director Jan 2024
    Mr Beazley is a former Australian politician and diplomat, serving as a Minister in the Hawke and Keating Labor Governments holding the portfolios of Defence, Finance and Special Minister of State, among others. Mr Beazley has also served as Deputy Prime Minister, Leader of the Australian Labor Party and Leader of the Opposition and, during his time in office, on parliamentary committees covering Intelligence, Foreign Affairs, Defence and Trade. He was appointed a Companion of the Order of Australia in 2009 for service to the Parliament of Australia and was appointed the 33rd Governor of Western Australian in 2018, serving in this role until 2022. Mr Beazley served as Ambassador to the United States of America between 2010 and 2016.His commercial service currently extends to Chair of the Perth US Asia Centre Board; Board Member of Luerssen Australia; Adviser to Lockheed Martin Australia; Chair of the Council for the Australian War Memorial; and Adviser to TG & Associates.
    Mr Peter Webse Company Secretary Mar 2023
    -
    Peter Webse Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Ming Hao Zheng & Fan Ying 6,805,886 3.45%
    Mr Paul Frederick Anderson & Ms Nicole Jane Telford 6,233,335 3.16%
    Mr Qixiao Zhou 5,996,241 3.04%
    Mr Jia Xun Xu 5,299,107 2.69%
    Sandhurst Trustees Ltd 4,913,939 2.49%
    Wenola Pty Ltd 3,934,058 1.99%
    Mr Patrick John McHale 3,657,147 1.85%
    Hsbc Custody Nominees (Australia) Limited 3,287,549 1.67%
    Citicorp Nominees Pty Ltd 2,057,820 1.04%
    Sankofa Strategic Equity Fund Limited 1,962,000 0.99%
    Mr Tony Athas & Mrs Angela Athas 1,600,000 0.81%
    Dr John Clifford Philpott 1,560,216 0.79%
    Dr John Clifford Philpott & Mrs Rebecca Anne Philpott 1,508,135 0.76%
    Mr Vance Clark Moore 1,350,000 0.68%
    BNP Paribas Nominees Pty Ltd 1,242,770 0.63%
    Mr Paul John Van Dyk 1,074,275 0.54%
    Mr Bryan F Short 1,068,200 0.54%
    Aris Nominees Pty Ltd 1,042,816 0.53%
    Bond Street Custodians Limited 1,000,000 0.51%
    Murdoch Ventures Pty Ltd 923,851 0.47%

    Profile

    since

    Note